<DOC>
	<DOC>NCT03097315</DOC>
	<brief_summary>Open-label safety study of suprachoroidal triamcinolone acetone injectable suspension in patients with non-infectious uveitis.</brief_summary>
	<brief_title>Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis</brief_title>
	<detailed_description>This is a Phase 3, open-label, multi-center study to assess the safety of 4 mg of CLS-TA administered via suprachoroidal injection for the treatment of subjects with non-infectious uveitis.</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Uveitis, Posterior</mesh_term>
	<mesh_term>Uveitis, Intermediate</mesh_term>
	<mesh_term>Pars Planitis</mesh_term>
	<mesh_term>Uveitis, Anterior</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Diagnosis of noninfectious uveitis (pan, anterior, intermediate and posterior) ETDRS BCVA score of â‰¥ 5 letters read in the study eye Any active ocular disease or infection in the study eye other than uveitis Intraocular pressure &gt; 22 mmHg or uncontrolled glaucoma in the study eye Any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>UME</keyword>
	<keyword>Posterior Uveitis</keyword>
	<keyword>Anterior Uveitis</keyword>
	<keyword>Intermediate Uveitis</keyword>
	<keyword>Panuveitis</keyword>
	<keyword>Non-infectious Uveitis</keyword>
	<keyword>Triamcinolone</keyword>
	<keyword>Choroid</keyword>
	<keyword>Choroidal Injection</keyword>
	<keyword>Suprachoroidal</keyword>
	<keyword>Microneedle</keyword>
	<keyword>Microinjection</keyword>
</DOC>